We have located links that may give you full text access.
Risk factors for malignancy and serious infection in patients with Inflammatory Bowel Disease: a retrospective analysis.
Internal Medicine Journal 2023 May 32
BACKGROUND: Patients with IBD patients are at increased risk of malignancy and infection compared to the general population.
AIMS: We aim to identify the risk factors for malignancy or serious infection in our IBD cohort.
METHODS: IBD patients at an adult tertiary referral centre were included. Demographic and clinical details including immunosuppressant exposure were collected and medical records were retrospectively screened for adverse events including malignancy or infection requiring hospitalisation. Logistic regression was used to evaluate risk factors for adverse events.
RESULTS: 549 patients with IBD [340 CD, 209 UC] were studied. Forty-eight malignancies, including 39 (81.3%) non-melanoma skin cancers (NMSC), 3 (6.3%) haematologic malignancies and 6 (15.4%) solid-organ malignancies were identified, and ninety-two cases of serious infection were detected. IBD disease duration (OR=1.08 95%CI:1.03-1.13) and ileocolonic Crohn's disease (OR=4.96 95%CI:1.13-21.71) were associated with increased odds of overall cancer. Compared with patients not previously exposed to the given class of immunosuppression assessed, the development of overall malignancy was not higher with thiopurine exposure (OR=1.00 95%CI:0.50-2.24) nor anti-TNF-alpha exposure (OR=0.78 95%CI:0.37-1.64).. Similarly, compared with patients not exposed, infection risk was not affected by thiopurine (OR=0.74 95%CI:0.46-1.20) nor anti-TNF exposure (OR=0.60 95%CI:0.38-0.95).
CONCLUSIONS: Factors including ileocolonic Crohn's disease and increasing IBD disease duration were associated with higher malignancy risk in this cohort. Compared with non-exposure, patients exposed to thiopurines were not at increased risk of malignancy or serious infection. Similarly, patients exposed to anti-TNF treatment did not experience increased rates of malignancy or serious infection compared to patients not exposed to this treatment. This article is protected by copyright. All rights reserved.
AIMS: We aim to identify the risk factors for malignancy or serious infection in our IBD cohort.
METHODS: IBD patients at an adult tertiary referral centre were included. Demographic and clinical details including immunosuppressant exposure were collected and medical records were retrospectively screened for adverse events including malignancy or infection requiring hospitalisation. Logistic regression was used to evaluate risk factors for adverse events.
RESULTS: 549 patients with IBD [340 CD, 209 UC] were studied. Forty-eight malignancies, including 39 (81.3%) non-melanoma skin cancers (NMSC), 3 (6.3%) haematologic malignancies and 6 (15.4%) solid-organ malignancies were identified, and ninety-two cases of serious infection were detected. IBD disease duration (OR=1.08 95%CI:1.03-1.13) and ileocolonic Crohn's disease (OR=4.96 95%CI:1.13-21.71) were associated with increased odds of overall cancer. Compared with patients not previously exposed to the given class of immunosuppression assessed, the development of overall malignancy was not higher with thiopurine exposure (OR=1.00 95%CI:0.50-2.24) nor anti-TNF-alpha exposure (OR=0.78 95%CI:0.37-1.64).. Similarly, compared with patients not exposed, infection risk was not affected by thiopurine (OR=0.74 95%CI:0.46-1.20) nor anti-TNF exposure (OR=0.60 95%CI:0.38-0.95).
CONCLUSIONS: Factors including ileocolonic Crohn's disease and increasing IBD disease duration were associated with higher malignancy risk in this cohort. Compared with non-exposure, patients exposed to thiopurines were not at increased risk of malignancy or serious infection. Similarly, patients exposed to anti-TNF treatment did not experience increased rates of malignancy or serious infection compared to patients not exposed to this treatment. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app